SB 5326
In CommitteeSenate
Insulin emergency supply
Accessing an emergency supply of insulin.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill creates a state-run emergency insulin program to provide one 30-day supply of insulin per year to eligible Washington residents who cannot afford it and have fewer than a 7-day supply on hand. The program is funded by insulin manufacturers, not state taxes.
- Establishes an emergency insulin program administered by the Health Care Authority, allowing eligible Washington residents to receive one 30-day supply of insulin per year for a maximum out-of-pocket cost of $10.
- Eligibility requires being a Washington resident, having a valid insulin prescription, having fewer than a 7-day supply of insulin, and not being enrolled in a plan that caps insulin copays/deductibles at $35 or less.
- Eligible individuals can attest to meeting criteria and receive an electronic voucher to redeem insulin at a network pharmacy.
- Pharmacies may charge up to $10 for dispensing and then submit claims to the prescription drug purchasing consortium for reimbursement, which must be paid within 30 days.
- Insulin manufacturers must reimburse the consortium for the cost of insulin provided, and the state may fine manufacturers up to $10,000 per failure to pay.
- The Health Care Authority must post information on manufacturer patient assistance programs on its website to help people access free or low-cost insulin.
Who is affected
- Uninsured or underinsured Washington residents with diabetes — Residents of Washington who need insulin but lack adequate insurance coverage that caps insulin costs at $35 or less per 30-day supply, and who have fewer than a 7-day supply on hand.
- Network pharmacies — Pharmacies that participate in the state’s prescription drug purchasing consortium and dispense insulin under the emergency program.
- Insulin manufacturers — Companies that manufacture insulin sold in Washington; they must pay for the insulin provided through the program.
- Washington State Health Care Authority and related state agencies — The state government, which administers the program and collects fines from noncompliant manufacturers.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Directly prevents insulin rationing and life-threatening complications (e.g., DKA, hospitalization, death) for low-income Washington residents with diabetes who lack adequate insurance coverage — a population that includes many hourly workers, gig economy employees, and people with disabilities. The $10 cap and attestation-based access remove financial and bureaucratic barriers that would otherwise exclude the most vulnerable.
HealthcarePeopleRef: Sec. 2(1), Sec. 2(2)(a)-(d), Sec. 2(4)(a)Shifts the financial burden of emergency insulin provision from individuals to insulin manufacturers, aligning with the 'polluter pays' principle — but the $10 dispensing fee and potential pharmacy participation hesitancy may limit net benefit to small pharmacies, and the program does not create new jobs.
Business & EmploymentPeopleRef: Sec. 2(6)(a)-(c), Sec. 2(7)Improves health equity by directing resources to those most at risk of insulin-related harm — particularly communities of color, rural residents, and people with Medicaid or non-Medicaid public coverage who may not qualify for $35 caps under private plans.
HealthcarePeopleRef: Sec. 2(8)Reduces medical debt risk for low-income households by preventing emergency room visits for insulin-related crises — though this is a secondary benefit, as housing instability and medical debt are strongly correlated.
HousingLean peopleRef: Sec. 2(1)Supports pharmacy solvency for participating network pharmacies by guaranteeing reimbursement within 30 days and allowing a $10 dispensing fee — but this benefit is modest and does not significantly improve overall pharmacy margins.
Business & EmploymentLean peopleRef: Sec. 2(5)(a)
Potential Concerns (5)
Provides critical, immediate access to life-saving insulin for low-income, underinsured, or uninsured Washington residents with diabetes who are at risk of insulin rationing or treatment interruption — a population disproportionately composed of people of color, rural residents, and those with disabilities. The $10 cap and attestation-based eligibility reduce administrative barriers, making the benefit accessible to those most in need.
HealthcarePeopleRef: Sec. 2(2)(d), Sec. 2(3), Sec. 2(4)(a)Mandates public disclosure of manufacturer patient assistance programs on the Health Care Authority website, improving transparency and helping eligible individuals navigate alternative (but often underutilized) free/low-cost insulin options — especially beneficial for those unfamiliar with complex pharmaceutical assistance systems.
HealthcarePeopleRef: Sec. 2(8)Allows network pharmacies to charge a $10 dispensing fee, which may help offset operational costs for small, independent pharmacies participating in the program — though this benefit is limited since the fee is capped and the program volume is uncertain.
Business & EmploymentLean peopleRef: Sec. 2(5)(a)Deposits manufacturer fines into the State Health Care Affordability Account, which could indirectly support future state health initiatives — but the amount is uncertain and not directly tied to local service delivery, limiting tangible local benefit.
Local GovernmentLean peopleRef: Sec. 2(7)Reduces risk of diabetic ketoacidosis (DKA) and emergency department visits due to insulin rationing, which can have public safety implications (e.g., reduced strain on EMS and ERs during crises) — though this is a secondary, indirect effect.
Public SafetyRef: Sec. 2(1)
Who Is Most Affected
This group — primarily low-income, underinsured, or uninsured Washingtonians with diabetes — stands to gain the most, avoiding life-threatening insulin rationing and catastrophic health complications. The program's $10 cap and attestation-based access are designed for this group, though the annual 30-day supply limit may not fully meet chronic needs.
Network pharmacies gain a guaranteed $10 dispensing fee and timely reimbursement, which may improve cash flow for participating pharmacies. However, the administrative burden and limited volume (one supply per person per year) may not offset operational costs for many, especially small or rural pharmacies.
Insulin manufacturers face direct financial liability for program costs and potential fines up to $10,000 per violation. While this aligns with accountability principles, it may incentivize manufacturers to lobby against broader coverage or increase list prices to offset costs — potentially harming long-term affordability.
The Health Care Authority gains new administrative responsibilities and authority to enforce manufacturer compliance, but the program is fully manufacturer-funded, reducing strain on state budgets. The fine revenue stream could support future health initiatives, though the scale is uncertain.
State taxpayers benefit indirectly from reduced emergency healthcare utilization and avoided long-term disability costs, but since the program is fully manufacturer-funded, there is no direct tax burden shift. The benefit is real but diffuse and hard to quantify.